Board and Management


Kjell G Stenberg


Kjell Stenberg, PhD served as Chief Operating Officer of Medwell Capital Corp. (also known as BioMS Medical Corp. developing a new drug in phase III studies for MS. In 2008 BioMS entered into a partnership with Eli Lilly that was awarded Licensing Deal Of the Year by Scrips. Previously, Dr. Stenberg served as Chief Executive Officer of Combio A/S. From 1975 to 2000, Dr. Stenberg served as Senior Researcher and Manager at Astra/AstraZeneca, where he was instrumental in bringing various drugs to market in the capacity of Director of Research or Director of Development. He is Chairman of Aptahem AB and board member of Novation Pharmacuticals and Galecto Biotech.

Ola Skanung


B Sc Business administration and Entrepreneurship and additional exams within financial law and Change Management. Skanung has many years of experience as CFO and working with start-ups and growth projects within the private as well as with state and regional development actors.


Bert Junno

Chairman of the board

Bert Junno is a co-founder of the life science companies: WntResearch AB (public), Galecto Biotech AB, Gabather AB (public), Aptahem AB (public) and Cyxone AB (public). He serves on the advisory board of the Swedish patent office since 2010. Bert Junno has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. Bert Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.

Theresa Comiskey Olsen

Board Member

Theresa Comiskey Olsen, Attorney at Law (USA), is a Partner at Nova Law Firm in Oslo, Norway. Before joining Nova, Comiskey Olsen was a partner at Langseth Law Firm since January 2016 after starting her own practice with focus on legal transactions in the Life Sciences/Biotech field. Prior to starting her practice in 2008, she was General Counsel of Nycomed, which has since been acquired by Takeda. Comiskey Olsen continues to grow her practice at Nova with focus on legal transactions in the Life Sciences/Biotech field. She has her B.A. from University of Pennsylvania and her J.D. from University of Detroit Mercy School of Law.

Saad Gilani

Board Member

Saad Gilani is a Managing Director at Yorkville Advisors Global and has been with the firm since 2005. As Head of the Healthcare Group, he has led financing transactions in a variety of life science companies focused on biotechnology, molecular diagnostics and medical devices in the US and in Europe. Gilani is a member of the firm’s Investment Committee. He also sits on the supervisory board of Temple Therapeutics BV based in The Netherlands.

Prior to joining Yorkville Advisors Global, Gilani worked at Keyence Corporation for 11 years where he held various management roles within the Engineering and Marketing groups. He earned a BSc in Electrical Engineering from Rutgers College of Engineering and received his MBA from Rutgers University in NJ, where he specialized in finance.

Mikael Lindstam

Board Member

Mikael Lindstam has been engaged in several start-up companies and development programs that have generated investments of more than 250 MSEK. Dr. Lindstam has been part of the development of Galecto Biotech AB and Gabather AB from Forskarpatent’s portfolio including a number of license deals and IP-divestments. Dr. Lindstam is a co-founder of Accequa AB and is currently board member and CEO of Aptahem AB and holds a Ph.D. in inorganic chemistry and with long experience from marketing, entrepreneurship and management.

Scientific advisory board

Christian gruber

Chairman of the scientific advisory

Christian Gruber is a research group leader and Associate Professor at the Medical University of Vienna (Austria). He studied Biochemistry at the University of Tübingen (Germany) and Molecular Biotechnology at the Queensland University of Technology (Australia), and received a PhD in Molecular Biosciences from The University of Queensland. For his achievements he received several scientific awards, e.g. the 2013 Heribert Konzett Award of the Austrian Pharmacological Society, the 2014 Young Investigator Silver Award of the International Union of Basic and Clinical Pharmacology, and the 2014 Dr. Willmar Schwabe Award of the Society for Medicinal Plant and Natural Product Research. The research focus of his team is to study biological function and pharmacological mechanism of nature-derived peptides isolated from plants and invertebrates (e.g., peptide hormones, neuropeptides and peptide toxins), and the development of novel peptide therapeutics. He is member of the scientific affairs committee of the European Peptide Society and member elect of the “Max-Bergmann-Kreis”.

Carsten Gründemann

Member of the scientific advisory

Carsten Gründemann is Head of the Division of Integrative Medical Research and Principal Investigator at the Center for Complementary at the Medical Center-University of Freiburg (Germany). He studied Biochemistry/Biology at the University of Tübingen and Freiburg (Germany) and received his Ph.D. in Experimental Immunology from the University of Tübingen (Germany). He received the Karl und Veronica Carstens (KVC) Science Award 2018 for his research in the field of complementary medicine for multiple sclerosis (MS). The research focus of his team is to study the immunological functions and mechanisms of traditional-used plants and fungi.